HJLI - Hancock Jaffe Laboratories, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.92
-0.05 (-1.68%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.97
Open2.95
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range2.92 - 3.10
52 Week Range2.79 - 5.64
Volume22,532
Avg. Volume217,927
Market Cap32.684M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.93
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer

    IRVINE, Calif., July 13, 2018-- Hancock Jaffe Laboratories, Inc., a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, ...

  • GlobeNewswire8 days ago

    Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve

    Hancock Jaffe Laboratories, Inc. (HJLI) (HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has initiated an analysis of its bioprosthetic heart valve in order to determine what additional testing is needed in order to submit an Investigational Device Extension (IDE) application to the United States Food and Drug Administration (FDA). The company has engaged Michael Nilo of Nilo Medical Consulting Group, to assist with the initial regulatory analysis. Mr. Nilo has significant insider experience with the FDA, having worked as a lead reviewer with the FDA’s cardiac medical device review team.

  • GlobeNewswire29 days ago

    Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study

    Hancock Jaffe Laboratories, Inc. (HJLI) (HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has selected Fundación Santa Fe de Bogotá (“FSFB”), in Bogota Columbia, as the site for first-in-human testing of its VenoValve(R) bioprosthetic medical device.   FSFB owns the 205 bed University Hospital in Bogota, which was the first hospital in Columbia to receive the distinguished Joint Commission International accreditation, and which is a research collaboration partner with John’s Hopkins Medical International.

  • GlobeNewswirelast month

    Hancock Jaffe Laboratories, Inc. Announces Full Exercise of $1,125,000 Underwriter’s Over Allotment

    Hancock Jaffe Laboratories, Inc. (HJLI) (HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that Network 1 Financial Securities, Inc., the managing underwriter for the company’s recent initial public offering (“IPO”), has exercised the full underwriters’ over-allotment option of 225,000 units, at the IPO price of $5.00 per unit.  Each unit consists of one share of common stock and a warrant to purchase one share of common stock. Gross proceeds from the exercise of the over-allotment option amount to $1,125,000 before underwriting discounts and commissions, bringing the total gross proceeds from the IPO to $8,625,000 before underwriting discounts and commissions.

  • GlobeNewswirelast month

    Hancock Jaffe Laboratories, Inc. Announces Closing of $7.5 Million Initial Public Offering

    Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced the closing of its previously announced initial public offering of 1,500,000 units, each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at an initial public offering price of $5.00 per unit. Gross proceeds from the IPO amount to $7,500,000 before underwriting discounts and commissions. HJLI has also granted the underwriters a 45-day option to purchase an additional 225,000 units at the initial public offering price, which if exercised, would generate another $1,125,000 of gross proceeds before underwriting discounts and commissions.

  • ACCESSWIRElast month

    Hancock Jaffe Laboratories (HJLI) Stock: A Flagship Product That Should Not Be Ignored!

    CORAL SPRINGS, FL / ACCESSWIRE / June 5, 2018 / The biotechnology space is one that's booming, with innovation seemingly around every corner. Nonetheless, even with all of the innovation taking place, ...

  • GlobeNewswire2 months ago

    Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering

    Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced the pricing of its initial public offering of 1,500,000 units, each unit consisting of one share of common stock and a warrant to purchase one share of common stock, at an initial public offering price of $5.00 per unit, before underwriting discounts and commissions. HJLI has also granted the underwriter a 45-day option to purchase an additional 225,000 units at the initial public offering price. Network 1 Financial Securities, Inc. is acting as sole book-running manager for the offering.